ALUMIS INC. (ALMS) Stock
4 of the hedge funds AlphaScala tracks reported ALMS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $27.25M. Company insiders reported 4 open-market buys and 8 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own ALMS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 968K | $27.25M | +69% |
| Millennium Management Israel Englander | 660K | $18.58M | +9% |
| Marshall Wace | 368K | $10.36M | -69% |
| Renaissance Technologies Jim Simons (founder) | 23K | $656.6K | -69% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are ALUMIS INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 8, 26 | Akkaraju Srinivas | Director | SELL | 48.1K | $507K |
| Sep 8, 26 | Akkaraju Srinivas | Director | SELL | 48.1K | $507K |
| Sep 8, 26 | Akkaraju Srinivas | Director | BUY | 273.3K | $2.9M |
| Sep 8, 26 | Akkaraju Srinivas | Director | BUY | 273.3K | $2.9M |
| Sep 4, 26 | Akkaraju Srinivas | Director | BUY | 220.1K | $2.5M |
| Sep 4, 26 | Akkaraju Srinivas | Director | BUY | 220.1K | $2.5M |
| Aug 3, 26 | Hardiman Roy C. | Chief Business & Strategy Ofcr | SELL | 2.7K | $71K |
| Aug 3, 26 | Schroer John R. | Chief Financial Officer | SELL | 3.3K | $87K |
| Aug 3, 26 | Goldstein David M | Chief Scientific Officer | SELL | 2.6K | $68K |
| Aug 3, 26 | Drappa Jorn | Chief Medical Officer | SELL | 2.4K | $65K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →ALMS price chart
Powered by TradingViewWhat does ALUMIS INC. do?
Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for immune-mediated diseases, aiming to replace broad immunosuppression with precision medicines. The company leverages its proprietary precision data analytics platform, biological insights, and expertise in immunology to advance a late-stage portfolio of next-generation treatments. Key pipeline assets include ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor targeting plaque psoriasis and systemic lupus erythematosus; A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases; and programs addressing interferon regulatory factor 5 (IRF5) to correct immune dysfunction. Alumis Inc. focuses on optimizing patient outcomes across autoimmune disorders through innovative drug discovery, development, and potential commercialization efforts. Founded in 2021 and headquartered in South San Francisco, California, the company plays a significant role in the biotechnology sector by pioneering therapies that transform treatment paradigms for chronic immune conditions.